Sol-Gel Investor Relations Material
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system. The company offers Phase 5 (clobex), a prescription liquid medication designed to selectively target specific classes of dendritic cells that initiate the immune response. Its smevetch is a topical compounded drug that contains tacrolimus and dexamethasone. The company was formerly known as Silex Platform Limited and changed its name to Sol-Gel Technologies Ltd. in June 2010. Sol-Gel Technologies Ltd. is based in London, the United Kingdom.
Edward "Ted" Decker's Rise to the Top at Home Depot
Explore Ted Decker's transformative impact on Home Depot, including his leadership in retail innovation and strategic vision alongside Craig Menear.
15 Feb 2024
Andy Jassy: Amazon CEO & Pioneer of Cloud Computing
Discover Andy Jassy's remarkable achievements at Amazon, including the creation of Amazon Web Services and his experiences working with Jeff Bezos.
15 Feb 2024
Stripe’s Rumored 2024 IPO
Anticipation grows around Stripe's rumored 2024 IPO, spotlighting its significant influence in the digital payments sector.
9 Feb 2024
🇺🇸 United States